CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma

Letizia Canu(Radboud University Nijmegen), Janna A W Van Hemert(Radboud University Nijmegen), Michiel N. Kerstens(University Medical Center Groningen), Robert P. Hartman(Mayo Clinic), Aakanksha Khanna(Mayo Clinic), Ivana Kraljević(University Hospital Centre Zagreb), Darko Kaštelan(University Hospital Centre Zagreb), Corin Badiu(Carol Davila University of Medicine and Pharmacy), Urszula Ambroziak(Medical University of Warsaw), Antoine Tabarin(Centre Hospitalier Universitaire de Bordeaux), Magalie Haissaguerre(Centre Hospitalier Universitaire de Bordeaux), Edward Buitenwerf(University Medical Center Groningen), Anneke Visser(University Medical Center Groningen), Massimo Mannelli(University of Florence), Wiebke Arlt(University of Birmingham), Vasileios Chortis(University of Birmingham), Isabelle Bourdeau(Centre Hospitalier de l’Université de Montréal), Nadia Gagnon(Centre Hospitalier de l’Université de Montréal), Marie Buchy(Hospices Civils de Lyon), Françoise Borson‐Chazot(Hospices Civils de Lyon), Timo Deutschbein(Universitätsklinikum Würzburg), Martin Faßnacht(Comprehensive Cancer Center Mainfranken), Alicja Hubalewska‐Dydejczyk(Jagiellonian University), Marcin Motyka(Jagiellonian University), Ewelina Rzepka(Jagiellonian University), Ruth Casey(Wellcome/MRC Institute of Metabolic Science), Benjamin Challis(Wellcome/MRC Institute of Metabolic Science), Marcus Quinkler, Laurent Vroonen(Centre Hospitalier Universitaire de Liège), Ariadni Spyroglou(Universitätsklinik für Diabetologie, Endokrinologie, Ernährungsmedizin & Metabolismus), Felix Beuschlein(Universitätsklinik für Diabetologie, Endokrinologie, Ernährungsmedizin & Metabolismus), Cristina Lamas(Hospital General Universitario de Albacete), William F. Young(Mayo Clinic), Irina Bancos(Mayo Clinic), Henri Timmers(Radboud University Nijmegen)
The Journal of Clinical Endocrinology & Metabolism
October 31, 2018
Cited by 128Open Access
Full Text

Abstract

Background: Up to 7% of all adrenal incidentalomas (AIs) are pheochromocytomas (PCCs). In the evaluation of AI, it is generally recommended that PCC be excluded by measurement of plasma-free or 24-hour urinary fractionated metanephrines. However, recent studies suggest that biochemical exclusion of PCC not be performed for lesions with CT characteristics of an adrenocortical adenoma (ACA). Aim: To determine the proportion of PCCs with ACA-like attenuation or contrast washout on CT. Methods: For this multicenter retrospective study, two central investigators independently analyzed the CT reports of 533 patients with 548 histologically confirmed PCCs. Data on tumor size, unenhanced Hounsfield units (HU), absolute percentage washout (APW), and relative percentage washout (RPW) were collected in addition to clinical parameters. Results: Among the 376 PCCs for which unenhanced attenuation data were available, 374 had an attenuation of >10 HU (99.5%). In the two exceptions (0.5%), unenhanced attenuation was exactly 10 HU, which lies just within the range of ≤10 HU that would suggest a diagnosis of ACA. Of 76 PCCs with unenhanced HU > 10 and available washout data, 22 (28.9%) had a high APW and/or RPW, suggestive of ACA. Conclusion: Based on the lack of PCCs with an unenhanced attenuation of <10 HU and the low proportion (0.5%) of PCCs with an attenuation of 10 HU, it seems reasonable to abstain from biochemical testing for PCC in AIs with an unenhanced attenuation of ≤10 HU. The assessment of contrast washout, however, is unreliable for ruling out PCC.


Related Papers

No related papers found

Powered by citation graph analysis